A Phase II Randomized Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence
Brief Description Of Study
This is a double-blind placebo-controlled clinical trial (n = 200) of varenicline for the treatment of cocaine dependence that utilizes contingency management to promote treatment attendance. Participants will be randomized (1:1) to receive varenicline (1.0 mg BID) for 12 weeks. Primary outcome measures include biochemically verified cocaine and nicotine use.